Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will host investor webcasts in January 2026 to review clinical and corporate updates.
Key events: a zanidatamab HERIZON-GEA-01 Phase 3 results webcast on Jan 9, 2026 at 6:30 a.m. PT / 3:30 p.m. GMT following the oral presentation at ASCO GI on Jan 8, 2026; and a corporate presentation by CEO Renee Gala at the J.P. Morgan Healthcare Conference on Jan 13, 2026 at 11:15 a.m. PST / 7:15 p.m. GMT.
Audio webcasts and 30-day replays will be available via the Investors section of Jazz Pharmaceuticals' website.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present eight abstracts, including four late-breaking posters, on Epidiolex (cannabidiol) at the American Epilepsy Society 2025 meeting (Dec 5–9, 2025) in Atlanta.
Key findings include a 6-month intermediate EpiCom analysis showing reductions in TAND-SQ and ABC subscale scores and caregiver/clinician‑reported behavioral severity after 26 weeks of adjunctive Epidiolex in tuberous sclerosis complex; a Phase 1 PK study finding no pharmacokinetic interaction between Epidiolex and cenobamate; preclinical synergistic PD effects with cenobamate; and multiple real-world analyses reporting reduced polypharmacy, antiseizure‑medication cycling, healthcare resource utilization, and seizure frequency versus external control.
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma will be presented as a late-breaking oral abstract at ASCO GI, Jan 8–10, 2026. The release notes highly statistically significant, clinically meaningful improvements in progression-free survival (PFS) for both Ziihera regimens versus trastuzumab plus chemotherapy, and statistically significant overall survival (OS) improvement for Ziihera plus tislelizumab and chemotherapy; Ziihera plus chemotherapy showed a clinically meaningful OS effect with a strong trend toward significance. A post-hoc OS analysis from HERIZON-BTC-01 in previously treated HER2+ biliary tract cancer will also be presented. Jazz will host an investor webcast on Jan 9, 2026 to review the data.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will participate in Citi's 2025 Global Healthcare Conference. Management will appear in a fireside chat on December 2, 2025 at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT. An audio webcast of the fireside chat will be available via the Investors section of Jazz Pharmaceuticals' website and a replay will be archived for 30 days.
Jazz Pharmaceuticals is a global biopharma focused on therapies for sleep disorders, epilepsy, and oncology, with R&D, manufacturing, and employees in multiple countries. For investor access, visit the company's investor events and presentations page.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced positive top-line Phase 3 HERIZON-GEA-01 results on Nov 17, 2025 for Ziihera (zanidatamab-hrii) in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma.
Both Ziihera+chemotherapy and Ziihera+tislelizumab+chemotherapy showed statistically significant PFS improvements versus trastuzumab+chemotherapy; the triplet also showed statistically significant OS benefit, while the doublet showed a clinically meaningful OS effect with a strong trend toward significance at first interim analysis. Jazz plans a U.S. sBLA submission in 1H 2026 and will seek guideline adoption and medical meeting presentation in early 2026.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting, November 19–23 in Honolulu.
Presentations highlight clinical and preclinical data for Modeyso (dordaviprone) in H3 K27M-mutant diffuse midline glioma, translational work on molecular pathways and combination strategies, immune‑modulatory effects, and new preclinical results for JZP3507 (ONC206) in CNS tumors.
Key sessions include oral and poster presentations on Nov 21–23 with multiple pediatric and rare tumor abstracts.
Jazz Pharmaceuticals (Nasdaq: JAZZ) reported 3Q25 total revenues of $1.126B, up 7% year‑over‑year, driven by Xywav, Epidiolex and the Modeyso launch. Modeyso received FDA accelerated approval and generated $11.0M in 3Q25 after an August launch. Xywav sales were $431.4M (+11%) and Epidiolex was $302.6M (+20%). GAAP net income for 3Q25 was $251.4M and non‑GAAP adjusted net income was $500.7M. Cash and investments were $2.0B with long‑term debt of $5.4B. Company narrowed 2025 revenue guidance to $4,175–$4,275M and provided updated GAAP and non‑GAAP guidance.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that Ted W. Love, M.D. will join the Board of Directors effective December 1, 2025. Dr. Love brings 30+ years of drug development and global commercialization experience, including leadership roles at Global Blood Therapeutics (CEO until its 2023 acquisition by Pfizer), Onyx, Nuvelo, and Genentech.
The appointment supports Jazz's stated board renewal effort—six directors have been appointed in the past five years—and coincides with the planned retirement of long-tenured director Kenneth O'Keefe, effective December 1, 2025.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will report its 2025 third quarter financial results on Wednesday, November 5, 2025 after the U.S. market close. Management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. GMT to discuss the results and provide a business and financial update.
Participants may register in advance via the Investors section of the Jazz Pharmaceuticals website and are recommended to register at least 15 minutes before the webcast. A replay will be available in the Investors events and presentations area.
Jazz Pharmaceuticals is a global biopharma company focused on therapies for sleep disorders, epilepsy, and oncology, headquartered in Dublin with global R&D and manufacturing operations.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced FDA approval on Oct 2, 2025 of Zepzelca (lurbinectedin) plus atezolizumab (or atezolizumab/hyaluronidase-tqjs) as the first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction with atezolizumab, carboplatin and etoposide.
The approval is based on Phase 3 IMforte results showing a 46% reduction in risk of progression or death and a 27% reduction in risk of death; median OS 13.2 vs 10.6 months (HR=0.73; p=0.0174) and median PFS 5.4 vs 2.1 months (HR=0.54; p<0.0001). The regimen was added to NCCN SCLC guidelines as a preferred maintenance option. Common adverse reactions (≥30%) include cytopenias, nausea, and fatigue.